Figure 7.

Percentage and geometric mean fluorescence intensity of cell subpopulations positive for ganglioside and neutral GSLs with terminal GalNAc residue. Notes Percentage of CSCs in the MDA-MB-231 and in the MDA-MB-453 (A) and non-CSCs in MDA-MB 231 and in the MDA-MB-453 cell lines (B). Geometric mean fluorescence intensity of CSCs in MDA-MB 231 and in the MDA-MB-453 (C) and non-CSCs in the MDA-MB-231 and in MDA-MB-453 cell lines after treatment with compound 1 in duration of 48 h. Data are expressed as a mean from experiment performed in triplicate ± SD. Columns, mean of viable cells; bars, SD; *P < 0.05; **P < 0.01, ***P < 0.001. CSC MDA-MB-231, CD44⁺CD24⁻ cells of the MDA-MB-231 cell line; CSC MDA-MB-453, CD133⁺ cells of the MDA-MB-453 cell line; non-CSC MDA-MB-231, CD44⁺/CD24⁺, CD44⁻/CD24⁻ and CD44⁻/CD24⁺ cells of the MDA-MB-231 cell line; non-CSC MDA-MB-453, CD133⁻ cells of the MDA-MB-453 cell line; globotetraosylceramide or Gb₄Cer, GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer; gangliotriaosylceramide or Gg₃Cer, GalNAcβ1-4Galβ1-4Glcβ1-1Cer; GM2, II³Neu5AcGg₃Cer; GalNAc-GM1b, IV³Neu5Ac-Gg₅Cer; GM1b, IV³Neu5Ac-Gg₄Cer; gangliotetraosylceramide or Gg₄Cer, Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer; GMI, geometric mean fluorescence intensity; SD, standard deviation.